New Tennessee Titans quarterback Vince Young didn't hold onto his draft day jersey for long.
He quickly passed it on to a 12-year-old fan.
Houston Texans linebacker coach Johnny Holland asked Young to visit with Archie Taylor Jr. The 12-year-old was diagnosed with lymphatic cancer in December.
Young autographed the jersey and called the meeting "a blessing."
Archie in turn promised to root for the Titans when they play the Texans. "It means a lot to me," he said. "I like his skills and how he plays. I like his friendship."
Young, who led the Longhorns to a win over Southern California in January's national championship game. "To see him smile right now, that's very exciting for me," he told Houston television station KRIV.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...